EZHIP is a specific diagnostic biomarker for posterior fossa ependymomas, group PFA and diffuse midline gliomas H3-WT with EZHIP overexpression
Open Access
- 5 November 2020
- journal article
- letter
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 8 (1) , 1-5
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- The pediatric supratentorial MYCN-amplified high-grade gliomas methylation class presents the same radiological, histopathological and molecular features as their pontine counterpartsActa Neuropathologica Communications, 2020
- Diffuse intrinsic pontine glioma-like tumor with EZHIP expression and molecular features of PFA ependymomaActa Neuropathologica Communications, 2020
- Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutationActa Neuropathologica, 2020
- EZHIP constrains Polycomb Repressive Complex 2 activity in germ cellsNature Communications, 2019
- An integrative radiological, histopathological and molecular analysis of pediatric pontine histone-wildtype glioma with MYCN amplification (HGG-MYCN)Acta Neuropathologica Communications, 2019
- EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymomaNeuro-Oncology, 2019
- Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomasActa Neuropathologica, 2018